| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | E. coli Shiga-like toxin II B subunit |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| Chemical and physical data | |
| Formula | C6414H9934N1718O2010S40 |
| Molar mass | 144556.44 g·mol−1 |
 
(what is this?)
(verify) | |
Urtoxazumab is a humanized monoclonal antibody against diarrhoea caused by Escherichia coli, serotype O121. The drug is designed to bind to a toxin of this bacterium, so that it can be more easily broken down and eliminated from the body. [1] [2]
References
- ^ "International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). World Health Organization.
- ^ López EL, Contrini MM, Glatstein E, González Ayala S, Santoro R, Allende D, et al. (January 2010). "Safety and pharmacokinetics of urtoxazumab, a humanized monoclonal antibody, against Shiga-like toxin 2 in healthy adults and in pediatric patients infected with Shiga-like toxin-producing Escherichia coli". Antimicrobial Agents and Chemotherapy. 54 (1): 239–43. doi: 10.1128/AAC.00343-09. PMC 2798559. PMID 19822704.
 | This antiinfective drug article is a stub. You can help Wikipedia by expanding it. |
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | E. coli Shiga-like toxin II B subunit |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| Chemical and physical data | |
| Formula | C6414H9934N1718O2010S40 |
| Molar mass | 144556.44 g·mol−1 |
|
(what is this?)
(verify) | |
Urtoxazumab is a humanized monoclonal antibody against diarrhoea caused by Escherichia coli, serotype O121. The drug is designed to bind to a toxin of this bacterium, so that it can be more easily broken down and eliminated from the body. [1] [2]
References
- ^ "International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). World Health Organization.
- ^ López EL, Contrini MM, Glatstein E, González Ayala S, Santoro R, Allende D, et al. (January 2010). "Safety and pharmacokinetics of urtoxazumab, a humanized monoclonal antibody, against Shiga-like toxin 2 in healthy adults and in pediatric patients infected with Shiga-like toxin-producing Escherichia coli". Antimicrobial Agents and Chemotherapy. 54 (1): 239–43. doi: 10.1128/AAC.00343-09. PMC 2798559. PMID 19822704.
|
| This antiinfective drug article is a stub. You can help Wikipedia by expanding it. |
|
| This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |